CoChat

Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial

Open access
Ruggenenti, Piero, Lauria, Giuseppe, Iliev, Ilian Petrov, Fassi, Anna, Ilieva, Aneliya Parvanova, Rota, Stefano, Chiurchiu, Carlos, Barlovic, Drazenka Pongrac, Sghirlanzoni, Angelo, Lombardi, Raffaella, Penza, Paola, Cavaletti, Guido, Piatti, Maria Luisa, Frigeni, Barbara, Filipponi, Marco, Rubis, Nadia, Noris, Greta, Motterlini, Nicola, Ene-Iordache, Bogdan, Gaspari, Flavio, Perna, Annalisa, Zaletel, Jelka, Bossi, Antonio, Dodesini, Alessandro Roberto, Trevisan, Roberto, Remuzzi, Giuseppe, for the DEMAND Study Investigators · 2011 · Hypertension
Cited by 103

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

To assess whether angiotensin-converting enzyme inhibitors and third-generation dihydropyridine calcium channel blockers ameliorate diabetic complications, we compared glomerular filtration rate (GFR; primary outcome), cardiovascular events, retinopathy, and neuropathy in 380 hypertensive type 2 diabetics with albuminuria <200 mg/min included in a multicenter, double-blind, placebo-controlled trial (DEMAND [Delapril and Manidipine for Nephroprotection in Diabetes]) and randomized to 3-year treatment with manidipine/delapril combination (10/30 mg/d; n=126), delapril (30 mg/d; n=127), or placebo (n=127). GFR was centrally measured by iohexol plasma clearance. Median monthly GFR decline (interquartile range [IQR]) was 0.32 mL/min per 1.73 m 2 (IQR: 0.16–0.50 mL/min per 1.73 m 2 ) on combined therapy, 0.36 mL/min per 1.73 m 2 (IQR: 0.18–0.53 mL/min per 1.73 m 2 ) on delapril, and 0.30 mL/min per 1.73 m 2 (IQR: 0.12–0.50 mL/min per 1.73 m 2 ) on placebo ( P =0.87 and P =0.53 versus combined therapy or delapril, respectively). Similar findings were observed when baseline GFR values were not considered for slope analyses. Albuminuria was stable in the 3 treatment groups. The hazard ratio (95% CI) for major cardiovascular events between combined therapy and placebo was 0.17 (0.04–0.78; P =0.023). Among 192 subjects without retinopathy at inclusion, the hazard ratio for developing retinopathy between combined therapy and placebo was 0.27 (0.07–0.99; P =0.048). Among 200 subjects with centralized neurological evaluation, the odds ratios for peripheral neuropathy at 3 years between combined therapy or delapril and placebo were 0.45 (0.24–0.87; P =0.017) and 0.52 (0.27–0.99; P =0.048), respectively. Glucose disposal rate decreased from 5.8±2.4 to 5.3±1.9 mg/kg per min on placebo ( P =0.03) but did not change on combined or delapril therapy. Treatment was well tolerated. In hypertensive type 2 diabetic patients, combined manidipine and delapril therapy failed to slow GFR decline but safely ameliorated cardiovascular disease, retinopathy, and neuropathy and stabilized insulin sensitivity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hypertensionaha.111.174474

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Metadata

Authors
Ruggenenti, P., Lauria, G., Iliev, I. P., Fassi, A., Ilieva, A. P., Rota, S., Chiurchiu, C., Barlovic, D. P., Sghirlanzoni, A., Lombardi, R., Penza, P., Cavaletti, G., Piatti, M. L., Frigeni, B., Filipponi, M., Rubis, N., Noris, G., Motterlini, N., Ene-Iordache, B., Gaspari, F., Perna, A., Zaletel, J., Bossi, A., Dodesini, A. R., Trevisan, R., Remuzzi, G., & for the DEMAND Study Investigators
Venue
Hypertension
Published
2011-11
Volume
58
Issue
5
Pages
776-783
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W2172091558
Cited by
103
References
8
FWCI
4.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial. https://app.cochat.ai/papers/10.1161/hypertensionaha.111.174474
The paper
Ruggenenti, P., Lauria, G., Iliev, I. P., Fassi, A., Ilieva, A. P., Rota, S., Chiurchiu, C., Barlovic, D. P., Sghirlanzoni, A., Lombardi, R., Penza, P., Cavaletti, G., Piatti, M. L., Frigeni, B., Filipponi, M., Rubis, N., Noris, G., Motterlini, N., Ene-Iordache, B., . . . for the DEMAND Study Investigators. (2011). Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial. Hypertension. https://doi.org/10.1161/hypertensionaha.111.174474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.